BU researcher awarded $7.2 million grant to develop mAb-based contraceptive products

Deborah Jean Anderson, PhD, professor of medicine at Boston University School of Medicine (BUSM), has received a four-year, $7.2 million grant from the NIH's National Institute of Child Health and Human Development renewing support for a Contraceptive Research Center (CRC) at BUSM to further her research to develop innovative monoclonal antibody (mAb)-based contraceptive and multipurpose prevention technology (MPT) products.

This research has the potential to improve the lives of millions of women globally by addressing two concurrent reproductive health crises: an unacceptably high rate of unintended pregnancies in both developing and developed countries and an epidemic of sexually transmissible infections."

Deborah Jean Anderson, PhD, professor of medicine at Boston University School of Medicine

With prior funding from the National Institute of Allergy and Infectious Diseases, Anderson and her team developed a vaginal film containing mAbs against HIV-1 and HSV-2 (herpes simplex virus type 2) that proved safe and effective in a Phase 1 clinical trial, and recently, with funding from her first CRC grant, Anderson developed an antisperm antibody for contraception. With this new award, Anderson plans to advance these products through advanced clinical trials.

For the past 40 years, Anderson has directed a research laboratory that studies reproductive health, mucosal immunology and HIV sexual transmission. Her laboratory was among the first to study immunological causes of infertility, and to identify risk factors for HIV transmission.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Using AI to foster productivity in pharmaceutical research and development